HSDD Genetics and Family History: Does Low Sexual Desire Run in Families?

What HSDD Actually Is, and Why the Definition Matters for Women

HSDD is persistent or recurrently low sexual desire that causes you personal distress, and that cannot be explained entirely by another medical condition, a relationship problem, or a medication side effect. That last word, "distress," is load-bearing. Low desire alone does not meet the threshold. The distress requirement protects against pathologizing normal variation, but it also means women who have made peace with low desire fall outside the clinical diagnosis even when genetics or biology may be contributing.

The DSM-5 merged the older HSDD label with Female Sexual Arousal Disorder into Female Sexual Interest/Arousal Disorder (FSIAD) for premenopausal women, but many clinicians and all FDA drug approvals still use the HSDD designation for both pre- and postmenopausal women. The Decreased Sexual Desire Screener (DSDS), a five-question validated tool, is now the standard first-line clinical screen recommended in office practice. A score suggesting generalized, acquired low desire with distress is the pattern most consistent with HSDD.

How Common Is It Across Life Stages?

Prevalence estimates vary because methodology differs, but the pattern is consistent. In the PRESIDE study, involving more than 31,000 U.S. Women, 8.9% of premenopausal and 12.3% of naturally postmenopausal women met criteria for HSDD with distress. Surgical menopause raised prevalence to approximately 26%. A 2019 analysis in Menopause confirmed that the sharpest increase in incidence tracks the menopausal transition, particularly the two years surrounding the final menstrual period.

Reproductive Years Versus Perimenopause

During your reproductive years, HSDD tends to be context-dependent. Postpartum hormonal shifts, oral contraceptive use, and undiagnosed thyroid disease or PCOS are common contributors. In perimenopause and post-menopause, declining estrogen and testosterone create a physiological floor that makes the condition harder to reverse without hormonal support. Understanding that distinction shapes both the genetic conversation and the treatment plan.

The Genetics of Female Sexual Desire: What the Evidence Actually Shows

Sexual desire is a complex trait, meaning many genes contribute small effects rather than one gene conferring HSDD. No single "low desire gene" has been identified, and direct-to-consumer genetic tests cannot meaningfully predict HSDD risk. What research does tell us is that genetic variation matters, particularly in neurotransmitter pathways.

Twin Studies and Heritability

The most methodologically rigorous evidence comes from twin studies, which allow researchers to separate genetic from environmental contributions. A study by Burri and colleagues published in Archives of Sexual Behavior examined more than 3,000 female twins and found that genetic factors accounted for approximately 31% of the variance in sexual desire, with non-shared environment explaining most of the rest. A separate Australian twin registry analysis placed heritability of sexual function broadly (including desire) at around 40 to 60 percent. These numbers tell you that if your mother or sister has HSDD, your own risk is meaningfully elevated, but the majority of variance still comes from experiences, relationships, and hormonal events that are not written into your DNA.

Dopamine, Serotonin, and the Neurobiological Pathways Under Study

Current genetic research in female sexual desire focuses on variants in genes regulating dopamine and serotonin signaling. Dopamine is excitatory for desire; serotonin is generally inhibitory. Polymorphisms in the serotonin transporter gene (SLC6A4) and dopamine receptor genes (DRD4, DRD2) have been associated with variability in sexual desire in small candidate-gene studies. A 2012 study found SLC6A4 promoter variants correlated with lower sexual satisfaction in women, consistent with the inhibitory role serotonin plays in desire circuitry. This is not a diagnostic test, but it is the biological rationale for why SSRIs so reliably suppress libido and why flibanserin, which modulates both serotonin and dopamine receptors, was designed as an HSDD treatment.

Hormonal Genetics: Androgen Receptor Variants and Estrogen Metabolism

Testosterone acts on desire through androgen receptors in the central nervous system. Variants in the androgen receptor gene (AR), particularly in the number of CAG trinucleotide repeats, affect receptor sensitivity. Women with shorter CAG repeat lengths (more sensitive receptors) tend to report higher sexual function scores, while longer repeat lengths are associated with lower desire, as shown in a 2006 study in the Journal of Sexual Medicine. Genetic variation in CYP19A1, the aromatase gene, also influences estrogen bioavailability from androgen precursors, meaning two women with identical total testosterone levels may experience very different estrogenic and androgenic effects depending on their CYP19A1 genotype.

A practical clinical framework: think of HSDD genetic risk in three layers. First, neurotransmitter pathway variants set a baseline excitatory-inhibitory tone for desire. Second, androgen and estrogen receptor genetics determine how sensitive your brain is to circulating sex hormones. Third, life events and hormonal milestones, including puberty, pregnancy, perimenopause, and exogenous hormones, interact with that genetic substrate to push you above or below the clinical threshold.

Evidence Gaps and What Is Extrapolated

Female sexual function has been understudied in genetics research. Most genome-wide association studies (GWAS) either excluded women, combined sexes without stratification, or focused on sexual orientation rather than desire. The candidate-gene findings described above come from studies with sample sizes of 200 to 800 women, which limits statistical power and reproducibility. A 2022 review in Sexual Medicine Reviews explicitly noted the absence of adequately powered GWAS specifically for female sexual desire as a critical gap. Clinically, this means any conversation about your "genetic risk" for HSDD should be framed as directional probability, not deterministic prediction.

Does Family History Change Your Diagnosis or Treatment?

Family history does not change the diagnostic criteria for HSDD, but it does change the clinical conversation in several ways.

Why Telling Your Clinician Matters

If your mother or sisters report persistent low desire, your provider should screen you earlier and more proactively at transitions, specifically when starting hormonal contraception, during the postpartum period, and at perimenopause. A family history of depression (which shares genetic architecture with low desire via serotonin pathways) is also clinically relevant because the two conditions co-occur at higher-than-chance rates. ACOG Practice Bulletin guidance on sexual health screening recommends integrating sexual function into routine reproductive health visits, a recommendation that applies across all life stages.

Laboratory Workup Worth Requesting

A family history of HSDD warrants a focused hormonal workup, including:

• Free and total testosterone (morning draw, follicular phase for premenopausal women)
• Sex hormone-binding globulin (SHBG), because high SHBG reduces free testosterone availability
• TSH (thyroid dysfunction mimics and worsens HSDD)
• FSH and estradiol if perimenopause is suspected
• Prolactin if secondary amenorrhea or galactorrhea is present

There is no validated "genetic panel" for HSDD available clinically. Research panels exist but are not standard of care.

HSDD Treatment: Options Across Life Stages

Treatment for HSDD is multimodal. The right combination depends on your reproductive stage, hormonal status, concurrent conditions, and personal priorities.

Premenopausal Women

Flibanserin (Addyi)

Flibanserin is the only FDA-approved daily oral treatment for premenopausal women with generalized, acquired HSDD. The VIOLET trial and its sister BEGONIA and SNOWDROP trials showed flibanserin increased the number of satisfying sexual events by approximately 0.5 to 1.0 events per month compared to placebo, with the most strong response in women who do not drink alcohol. The drug is a 5-HT1A agonist and 5-HT2A antagonist with dopamine D4 agonism. Its mechanism directly targets the neurotransmitter pathways implicated in genetic studies.

Flibanserin 100 mg taken at bedtime is the standard dose. Side effects include dizziness, nausea, and somnolence, particularly if taken with alcohol or moderate-to-strong CYP3A4 inhibitors such as fluconazole.

Bremelanotide (Vyleesi)

Bremelanotide is an on-demand subcutaneous injection taken 45 minutes before anticipated sexual activity. It acts on melanocortin receptors (MC3R and MC4R) in the hypothalamus to increase sexual desire independent of hormonal levels. The RECONNECT trials found that women using bremelanotide reported significantly greater desire and significantly less distress compared to placebo. Nausea is the most common side effect, affecting approximately 40% of users. A prophylactic antiemetic is often prescribed alongside it.

Hormonal Contraception and HSDD

Combined oral contraceptives raise SHBG, which reduces free testosterone and may worsen HSDD in genetically susceptible women. Switching to a progestin-only method or a non-hormonal method such as a copper IUD can be a diagnostic maneuver as well as a therapeutic one. If low desire began within three months of starting a new hormonal contraceptive, the contraceptive is the most likely driver.

Perimenopausal Women

Perimenopause is the highest-risk period for new-onset HSDD. Estradiol fluctuates dramatically before declining, and testosterone falls in parallel. The Menopause Society (formerly NAMS) 2022 Position Statement acknowledges that systemic estrogen therapy improves overall sexual function partly by restoring vulvovaginal health and mood, though direct desire-specific effects are modest.

Testosterone therapy is not FDA-approved for women in the United States but has the strongest evidence base for postmenopausal HSDD. A 2019 systematic review and meta-analysis by Davis and colleagues in The Lancet Diabetes and Endocrinology covering 36 randomized trials found that testosterone significantly improved sexual desire, arousal, orgasm, and pleasure compared to placebo or comparator in postmenopausal women. Doses studied were low, targeting a female physiologic range rather than male reference ranges.

Postmenopausal Women

Postmenopausal HSDD has the strongest hormonal driver of any life stage. Options include:

• Systemic estrogen therapy (patches, gels, oral) for women without contraindications
• Ospemifene (Osphena), an oral SERM approved for dyspareunia that also improves desire in some women with genitosystemic menopause symptoms
• Off-label testosterone via compounded creams or gels, dosed to achieve mid-normal premenopausal female levels
• Psychosexual therapy, particularly mindfulness-based cognitive therapy, which has shown efficacy in RCT data for women with low desire regardless of menopausal status

Bremelanotide's labeling specifies premenopausal women, and flibanserin's FDA approval is also limited to premenopausal women. Postmenopausal women may use these agents off-label, but published trial data in this population are limited. Your provider should make that distinction clear.

PCOS and HSDD

Women with PCOS have higher androgen levels but frequently report lower sexual desire than women without PCOS, a paradox explained partly by elevated SHBG in some PCOS phenotypes and partly by body image concerns and depression that accompany the diagnosis. A 2021 study in Fertility and Sterility found HSDD prevalence in PCOS cohorts was approximately 15%, higher than in age-matched controls. Androgen receptor polymorphisms may mediate why some women with PCOS convert high androgens into desire-enhancing central signaling while others do not.

Postpartum Women

Postpartum HSDD is nearly universal in the first 6 to 12 weeks and affects up to 50% of women at 12 months postpartum, particularly those who are breastfeeding. Lactation suppresses estrogen and testosterone via prolactin-mediated GnRH inhibition. This is physiologic, not pathologic, in most cases. If low desire persists beyond 12 months postpartum despite weaning, a formal HSDD evaluation is appropriate. Neither flibanserin nor bremelanotide has been studied in lactating women, and both should be avoided during breastfeeding.

Pregnancy, Lactation, and Contraception: What You Must Know

Flibanserin is contraindicated in pregnancy. Animal studies showed fetal harm at doses comparable to the human therapeutic dose, and there are no adequate human pregnancy data. The FDA label requires discontinuation before attempting conception.

Bremelanotide is also contraindicated in pregnancy. Animal studies at doses 16 times the human dose showed fetal growth restriction and limb abnormalities. FDA labeling states that women of reproductive potential should use effective contraception during treatment and discontinue bremelanotide if pregnancy is confirmed.

Neither drug has lactation transfer data in humans. Given the absence of safety data and the availability of alternative postpartum supports, both should be avoided while breastfeeding.

Off-label testosterone in women carries a category X designation in pregnancy due to the risk of female fetal virilization. Women using compounded testosterone for HSDD must use reliable contraception unless they are postmenopausal or have confirmed infertility. This point is frequently omitted in clinical discussions, and it is clinically critical.

If you are trying to conceive and experiencing HSDD, psychosexual therapy and treatment of underlying hormonal contributors (thyroid, prolactin, PCOS-related androgen imbalance) are the first-line options because they carry no fetal risk.

Who This Is Right For, and Who Should Pause

Most Likely to Benefit From Medical Evaluation

• Women with generalized, acquired low desire (desire was present previously and has declined) causing personal distress
• Women with a first-degree family history of HSDD or depression, particularly at hormonal transitions
• Perimenopausal or postmenopausal women whose desire decline tracks the menopausal transition
• Women with PCOS, thyroid disease, or hyperprolactinemia who have not had sexual function assessed
• Women whose low desire began or worsened after starting hormonal contraception

Cases Requiring a Different First Step

• Situational low desire (only low with a specific partner or context) is more likely a relationship or psychological issue than a genetic or hormonal one.
• Women whose low desire is better explained by an untreated mood disorder should address the mood disorder first; antidepressants other than SSRIs or SNRIs, such as bupropion, may have a less suppressive or even desire-enhancing effect.
• Women who are not distressed by low desire do not have HSDD by definition and do not need treatment.

As WomanRx reviewer Dr. Rachel Goldberg, MD, puts it: "The genetic data give us permission to stop framing low desire as a personal failure. When a woman tells me her mother never wanted sex and she doesn't either, that pattern is real and biological. But genetics is not destiny. The same woman often responds well to testosterone optimization or a switch in her contraception method."